- Home
- RYOJ vs BTAI Comparison
RYOJ vs BTAI Comparison
Compare RYOJ & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | BTAI |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 35.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RYOJ | BTAI |
|---|---|---|
| Price | $2.04 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 14.9K | ★ 887.6K |
| Earning Date | 12-15-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $1.01 |
| 52 Week High | $11.43 | $8.08 |
Technical Indicators
Market Signals| Indicator | RYOJ | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 49.83 |
| Support Level | $1.90 | $1.02 |
| Resistance Level | $2.53 | $1.26 |
| Average True Range (ATR) | 0.33 | 0.09 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 4.17 | 54.29 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.